Prostate Cancer

Generex sub presents promising data on efficacy of DNA vaccine technology

Published in Gene Therapy Weekly, January 29th, 2004

Generex Biotechnology Corp. (GNBT) announced that Antigen Express, Inc., its wholly owned subsidiary, recently presented a poster on its DNA vaccine technology for cancer at the U.S. National Institutes of Health conference titled, "Innovative Administrative Systems for Vaccines."

Robert Humphreys, MD, PhD, executive VP and chief scientific officer of Antigen Express, delivered the presentation in a poster that illustrated the benefits of using Antigen Express's proprietary and patented Ii protein antisense reagents to induce a T helper cell response to prostate cancer antigens.

The therapy cured about half of the mice with an aggressive, poorly...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-01-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry